Early retinal and choroidal effect of photodynamic treatment in patients with polypoidal choroidal vasculopathy with or without anti-vascular endothelial growth factor: An optical coherence tomography angiography study.


Journal

Photodiagnosis and photodynamic therapy
ISSN: 1873-1597
Titre abrégé: Photodiagnosis Photodyn Ther
Pays: Netherlands
ID NLM: 101226123

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 27 08 2018
revised: 27 09 2018
accepted: 09 10 2018
pubmed: 24 10 2018
medline: 18 12 2019
entrez: 24 10 2018
Statut: ppublish

Résumé

To evaluate the early retinal and choroidal effects of the anti-vascular endothelial growth factor (anti-VEGF) therapy combined with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). Patients diagnosed as having PCV were included in the study. In group 1, intravitreal ranibizumab and PDT was applied to six eyes. In group 2, PDT treatment only was applied to four eyes. Optical coherence tomography (OCT) angiography images and best-corrected visual acuity (BCVA) were taken from all patients before treatment and 3 days after surgery. The mean age of the patients was 66.00 ± 6.28 years. In group 1, the initial BCVA was 0.70 ± 0.35 logMAR and the final BCVA was 1.1 ± 0.78 logMAR. In group 2, the initial BCVA was 0.47 ± 0.17 logMAR and the final BCVA was 0.50 ± 0.21 logMAR. In group 1, flow rate significantly decreased in the superficial area (p = 0.028), the flow rate also decreased in other layers but they were not statistically significant (p < 0.05). In group 2, the flow rate decreased but these changes were not statistically significant (p > 0.05). Vascular constriction and choroidal ischemia were seen in two patients in group 1. In the short term, retinal and choroidal blood flow decreased after PDT treatment. However, statistically significant changes were seen only in the superficial area in group 1.

Identifiants

pubmed: 30352287
pii: S1572-1000(18)30278-3
doi: 10.1016/j.pdpdt.2018.10.007
pii:
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0
Verteporfin 0X9PA28K43
Ranibizumab ZL1R02VT79

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Erdem Eris (E)

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Turkey. Electronic address: erdem-eris@hotmail.com.

Esra Vural (E)

Mardin Government Hospital, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH